Skip to main content
. 2016 Jun 15;4(2):76–82. doi: 10.14218/JCTH.2016.00011

Table 3. Treatment regimens.

Characteristics Overall Approved n/N (%) Denied n/N (%)
Treatment regimen N = 332 N = 78
Ledipasvir/Sofosbuvir 324 261/332(78.6%) 63/78 (80.8%)
Ledipasvir/Sofosbuvir + Ribavarin 39 30/332 (9.0%) 9/78 (11.5%)
Sofosbuvir + Ribavarin 37 33/332 (9.9%) 4/78 (5.1%)
Sofosbuvir + Simeprevir 2 1/332 (0.3%) 1/78 (1.3%)
3D 12 6/332 (1.8%) 6/78 (7.7%)
3D + Ribavarin 3 1/332 (0.3%) 2/78 (2.6%)

Abbreviation: 3D, Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir.

HHS Vulnerability Disclosure